ID

22715

Beskrivning

Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01578902

Länk

https://clinicaltrials.gov/show/NCT01578902

Nyckelord

Versioner (1)
  1. 2017-06-10 2017-06-10 -
Uppladdad den

10 juni 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Prostate Cancer NCT01578902

Engelsk

Eligibility Prostate Cancer NCT01578902

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent signed (appendix a)
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
adult men greater than 18 years of age
Beskrivning

Gender | Adult | Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001675
UMLS CUI [3]
C0001779
histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally reviewed).
Beskrivning

Adenocarcinoma of prostate

Datatyp

boolean

Alias
UMLS CUI [1]
C0007112
clinical stage t1-t2b, gleason score < 6, and psa < 10 ng/ml
Beskrivning

TNM clinical staging | Gleason score | Prostate specific antigen measurement

Datatyp

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2]
C3203027
UMLS CUI [3]
C0201544
less than 50% of biopsy cores +ve for cancer
Beskrivning

Biopsy Percentage Positive Malignant Neoplasms

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0005558
UMLS CUI [1,2]
C0439165
UMLS CUI [1,3]
C1514241
UMLS CUI [1,4]
C0006826
less than 50% overall surface area involved with cancer
Beskrivning

Body Surface Area Percentage Involvement with Malignant Neoplasms

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0005902
UMLS CUI [1,2]
C0439165
UMLS CUI [1,3]
C1314939
UMLS CUI [1,4]
C0006826
neoadjuvant hormone suppression therapy is allowed. however, psa, must have been performed within 2 months of starting androgen suppression therapy. if androgen suppression therapy has been started lhrh agonist must be continued for a minimum of 3 months before initiation of gold fiducial marker insertion & radiotherapy planning.
Beskrivning

Hormone suppression therapy Neoadjuvant | Prostate specific antigen measurement | Androgen suppression | Luteinizing Hormone-releasing Hormone Agonist | Therapeutic radiology procedure Planned

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1535931
UMLS CUI [1,2]
C0600558
UMLS CUI [2]
C0201544
UMLS CUI [3]
C1515985
UMLS CUI [4]
C1518041
UMLS CUI [5,1]
C1522449
UMLS CUI [5,2]
C1301732
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior pelvic radiotherapy.
Beskrivning

Radiotherapy to pelvis

Datatyp

boolean

Alias
UMLS CUI [1]
C1536155
concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed insertion)
Beskrivning

Anticoagulants

Datatyp

boolean

Alias
UMLS CUI [1]
C0003280
diagnosis of bleeding diathesis
Beskrivning

Bleeding tendency

Datatyp

boolean

Alias
UMLS CUI [1]
C1458140
presence of a hip prosthesis
Beskrivning

Hip Prosthesis

Datatyp

boolean

Alias
UMLS CUI [1]
C0019560
pelvic girth >40cm (to ensure visibility of gold seeds on electronic portal imaging device)
Beskrivning

Pelvis Measurement of girth

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0030797
UMLS CUI [1,2]
C0203911
large prostate (> 60 cm3) on imaging
Beskrivning

Large prostate Imaging

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0426732
UMLS CUI [1,2]
C0011923
severe lower urinary tract symptoms (international prostate symptom score > 15 or nocturia > 3)
Beskrivning

Lower Urinary Tract Symptoms Severe International prostate symptom score | Nocturia

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0574785
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C1998280
UMLS CUI [2]
C0028734
Tillbaka till toppen

Similar models

Eligibility Prostate Cancer NCT01578902

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent signed (appendix a)
boolean
C0021430 (UMLS CUI [1])
Gender | Adult | Age
Item
adult men greater than 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001675 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
Adenocarcinoma of prostate
Item
histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally reviewed).
boolean
C0007112 (UMLS CUI [1])
TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
clinical stage t1-t2b, gleason score < 6, and psa < 10 ng/ml
boolean
C3258246 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0201544 (UMLS CUI [3])
Biopsy Percentage Positive Malignant Neoplasms
Item
less than 50% of biopsy cores +ve for cancer
boolean
C0005558 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,4])
Body Surface Area Percentage Involvement with Malignant Neoplasms
Item
less than 50% overall surface area involved with cancer
boolean
C0005902 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C1314939 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,4])
Hormone suppression therapy Neoadjuvant | Prostate specific antigen measurement | Androgen suppression | Luteinizing Hormone-releasing Hormone Agonist | Therapeutic radiology procedure Planned
Item
neoadjuvant hormone suppression therapy is allowed. however, psa, must have been performed within 2 months of starting androgen suppression therapy. if androgen suppression therapy has been started lhrh agonist must be continued for a minimum of 3 months before initiation of gold fiducial marker insertion & radiotherapy planning.
boolean
C1535931 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
C1515985 (UMLS CUI [3])
C1518041 (UMLS CUI [4])
C1522449 (UMLS CUI [5,1])
C1301732 (UMLS CUI [5,2])
Item Group
C0680251 (UMLS CUI)
Radiotherapy to pelvis
Item
prior pelvic radiotherapy.
boolean
C1536155 (UMLS CUI [1])
Anticoagulants
Item
concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed insertion)
boolean
C0003280 (UMLS CUI [1])
Bleeding tendency
Item
diagnosis of bleeding diathesis
boolean
C1458140 (UMLS CUI [1])
Hip Prosthesis
Item
presence of a hip prosthesis
boolean
C0019560 (UMLS CUI [1])
Pelvis Measurement of girth
Item
pelvic girth >40cm (to ensure visibility of gold seeds on electronic portal imaging device)
boolean
C0030797 (UMLS CUI [1,1])
C0203911 (UMLS CUI [1,2])
Large prostate Imaging
Item
large prostate (> 60 cm3) on imaging
boolean
C0426732 (UMLS CUI [1,1])
C0011923 (UMLS CUI [1,2])
Lower Urinary Tract Symptoms Severe International prostate symptom score | Nocturia
Item
severe lower urinary tract symptoms (international prostate symptom score > 15 or nocturia > 3)
boolean
C0574785 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1998280 (UMLS CUI [1,3])
C0028734 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial